Anti-CD40L [hu5c8 (Ruplizumab)]

Absolute Antibody

Anti-CD40L [hu5c8 (Ruplizumab)]

9

The antibody binds to CD40L with an IC50 of 0.845 ug/ml.

The antibody binds specifically to CD40L, a surface receptor expressed on activated T cells which acts as a costimulatory molecule to trigger immune responses. The antibody neutralises CD40L function, as it blocks the interaction between CD40 and CD40L. When injected into cynomolgus monkeys, the original therapeutic antibody was found to have a T1/2 of 531 +/- 155 hours.

Flow Cytometry, Western Blot, Neutralisation/Blocking

Research Use Only

Monoclonal

hu5c8 (Ruplizumab)

CD40LG

CD40 ligand

CD154; CD40 antigen ligand; CD40 ligand; CD40L; CD40-L; gp39; hCD40L; HIGM1; IGM; IMD3; T-B cell-activating molecule; T-BAM; T-cell antigen Gp39; TNF-related activation protein; TNFSF5; TRAP; tumor necrosis factor (ligand) superfamily member 5

Mouse

IgG1

CD40 ligand

NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Human

-20°C,2°C to 8°C

12352203